US4203992A
Expired / Lapsed
US
⏱️ 0.0 years remaining
β-Bromopenicillanic acid sulfone
Assignee: ER Squibb and Sons LLC
•
Filing: 1978-12-11
•
Granted: 1980-05-20
•
Expires: 1998-12-11
Abstract
Abstract (2S,5R,6S)-6β-Bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, physiologically acceptable salts thereof and readily hydrolyzable ester thereof inhibit the action of the β-lactamase enzyme RTEM.
Inventors
- 👤 Eric M. Gordon
- 👤 William H. Koster
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 18:55
CPC Classifications
C; C07; C07D; C07D499/00; A; A61; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
15 words
(2S,5R,6S)-6.beta.-Bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof.
Claim 2
Dependent Claim
15 words
(2S,5R,6S)-6.beta.-Bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof.
Claim 3
Dependent Claim
10 words
A compound in accordance with claim 1, (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid, S,S-dioxide.
Claim 4
Independent Claim
54 words
A method of inhibiting the action of the β-lactamase enzyme RTEM in a mammalian host being treated with a β-lactam antibiotic susceptible to degradation by the RTEM enzyme, which comprises administering (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof to the host in conjunction with the antibiotic.
Claim 5
Independent Claim
54 words
A method of inhibiting the action of the β-lactamase enzyme RTEM in a mammalian host being treated with a β-lactam antibiotic susceptible to degradation by the RTEM enzyme, which comprises administering (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof to the host in conjunction with the antibiotic.
Claim 6
Dependent Claim
14 words
A method in accordance with claim 3 wherein the compound is (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide.
Claim 7
Dependent Claim
30 words
A composition comprising a β-lactam antibiotic susceptible to degradation by the β-lactamase enzyme RTEM and (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof.
Claim 8
Dependent Claim
30 words
A composition comprising a β-lactam antibiotic susceptible to degradation by the β-lactamase enzyme RTEM and (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, or a physiologically acceptable salt thereof or a readily hydrolyzable ester thereof.
Claim 9
Dependent Claim
22 words
A composition in accordance with claim 5 comprising a β-lactam antibiotic susceptible to degradation by the β-lactamase enzyme and (2S,5R,6S)-6β-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid, S,S-dioxide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-05-20 | 1983-11-19 | 1984-05-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-05-20 | 1987-11-19 | 1988-05-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-05-20 | 1991-11-19 | 1992-05-20 | $7700.00 | Window Closed / Lapsed |